Sera from 735 patients with systemic sclerosis were classi®ed according to antinuclear antibody (ANA) pattern as follows: centromere (25%), homogeneous (26%), ®ne speckled (21%), ®ne speckled with nucleolar (14%), coarse speckled (7%), nucleolar only (3%) and cytoplasmic only (3%). Immunoprecipitations using 35 S-labelled HeLa cell antigen extract were performed using sera from 374 of these patients to detect the systemic sclerosis-speci®c antibodies to RNA polymerases I and III. The sera were selected to represent each ANA group, but focused on those giving ®ne speckled nucleoplasmic staining (with or without nucleolar staining) where all 86 sera positive for these antibodies were concentrated. Immunoprecipitates from a further 93 sera from patients with ANA-positive autoimmune diseases other than systemic sclerosis did not precipitate RNA polymerases. In addition, all sera were tested for antibodies to the extractable nuclear antigens topoisomerase I, nRNP, Ro, La and PM-Scl. Sera positive for antibodies to these antigens gave clear correlations with ANA patterns but, of the examples tested, none contained antibodies precipitating RNA polymerase I or III. Thus, sera containing antibodies to RNA polymerases I and III were exclusive of both anticentromere and anti-topoisomerase I, and formed a major serological subgroup (11.7%). Clinically, 77% were patients with diuse cutaneous disease re¯ected by higher skin scores and a signi®cantly higher incidence of renal involvement (33%) than patients with antibodies to topoisomerase I (3%).
SYSTEMIC sclerosis (SSc) is an autoimmune disease characterized by thickening and ®brosis of the skin and internal organs, the severity of which varies considerably between individuals [1] . This clinical heterogeneity causes considerable management problems and an important aspect of disease classi®cation is to identify groups of individuals likely to follow a particular clinical course. Virtually all patients are now recognized as having antinuclear antibodies (ANA) and the various speci®cities have been shown to be useful in the identi®cation of disease subsets [2] . The most common SSc-speci®c antibodies, anticentromere (ACA) and anti-topoisomerase I (ATA), have been predominantly associated with limited cutaneous disease (lcSSc) and diuse cutaneous disease (dcSSc), respectively, and their mutual exclusiveness has been well documented [3] . Antibodies to PM-Scl and nRNP are also present in SSc; they are less frequent and associated with overlap syndromes that show features of polymyositis (PM) and systemic lupus erythematosus (SLE) [4] . More recently, three further SSc-speci®c antibodies reacting with U3-RNP, Th-RNP and RNA polymerases have been described. Whereas anti-U3 and anti-Th are relatively rare, antibodies to RNA polymerases (ARA) represent a major antibody category with distinct clinical features [4±7] .
The three mammalian RNA polymerases (I, II, III) (RNAP) are enzymes with multiple subunits distinguishable from each other by the resolution in polyacrylamide gel of characteristic bands for the two largest subunits of each enzyme (190 and 120 kDa for RNAP I, 220 and 145 kDa for RNAP II, 155 and 138 kDa for RNAP III). The antibodies precipitating RNAP I and III have also been shown to be speci®c for SSc, de®ning patients who typically have dcSSc, major organ involvement and a poor prognosis [8, 9] . Antibodies to RNAP II occur in SSc, but are not disease speci®c [10, 11] . They recognize at least two epitopes, one of which is formed by the phosphorylation of the 220 kDa subunit. Antibodies to this phosphorylated form of RNAP II (RNAP IIO) are found in association with ATA in SSc, but are also present in other connective tissue diseases [12] . Antibodies to the non-phosphorylated form occur in association with ARA (I and III).
In this study, we report our experience of immunoprecipitating the SSc-speci®c ARA (I and III), thereby excluding the RNAP II antibodies that react with RNAP IIO, and detail the main clinical features of these patients in comparison to patients with ATA.
METHODS

Patients
Sera from 735 patients ful®lling the ARA criteria for the classi®cation of SSc [13] were assessed for the presence of ANA and antibodies to extractable nuclear antigens (ENA). Further analysis, limited by the availability of the 35 S-labelled HeLa cell antigen extract, was undertaken on sera from 374 SSc patients by immunoprecipitation. These were selected by ANA pattern without any prior knowledge of clinical disease. We also performed ANA, immuno- 
Clinical features
Patients with SSc were classi®ed as either dcSSc, showing skin sclerosis proximal to the elbows and extending towards the trunk, or lcSSc, characterized by skin sclerosis restricted to the extremities and face [14] . Clinical severity was assessed according to an internationally validated system [15] with involvement being de®ned as at least grade one severity within each individual system. The duration of SSc was taken as the time from onset of the ®rst de®nite nonRaynaud's symptom. For the patients studied, respiratory involvement was de®ned as >30% reduction from the predicted carbon monoxide transfer factor or forced vital capacity, or by other con®rmatory evidence of ®brosis, such as amorphous or reticuloanodular in®ltrates on high-resolution computed tomography. Cardiac involvement was determined by an ejection fraction of under 65% by echocardiography or by a signi®cant arrhythmia or conduction defect. Renal involvement was recorded if there was any history of hypertensive renal crisis attributable to SSc, even if subsequent recovery was full, or where there was persistent otherwise inexplicable renal impairment or proteinuria. Myositis was de®ned by the presence of at least two of the following: signi®cant proximal weakness (power below MRC grade three), abnormal electromyography, elevated serum creatinine kinase or histological evidence of myositis on biopsy. Gastrointestinal tract involvement was invariably present in all patients and determined by symptoms of oesophagitis or abnormal motility on scintiscan [16] . All SSc patients were examined for isolated pulmonary hypertension de®ned by reduction of carbon monoxide transfer factor with a normal forced vital capacity associated with characteristic Doppler echocardiographic features [17] ; however, no cases of isolated pulmonary hypertension were seen in patients with ARA or ATA included in the comparative study. Skin involvement was assessed by scoring each of 20 areas as normal=0, possible thickening=1, de®nite thickening=2 or hidebound=3, to give a maximum score of 60 [18] .
Indirect immuno¯uorescence ANA testing
Sera were diluted at 1/100 in phosphate-buered saline (PBS) [150 mM NaCl, 10 mM phosphate (pH 7.
2)] and screened by indirect immuno¯uorescence [19] using a HEp-2 cell substrate (Bion Inc., Park Ridge, IL, USA) with rabbit anti-human polyvalent uorescein isothiocyanate conjugate (F0200, Dako, Ely) and viewed at Â400 magni®cation under a¯u orescence microscope (Carl Zeiss, Oberkochen, Germany).
Anti-ENA estimation
Counterimmunoelectrophoresis (CIE) for anti-ENA was performed as previously described using soluble extracts from human spleen and rabbit thymus acetone powder (Pelfreez Biologicals, Rogers, AR, USA) as antigen [20] and antisera of con®rmed speci®city [21] .
Immunoprecipitation
Immunoprecipitation from [
35 S]Met-labelled HeLa cell extract was performed essentially as described [7] . Brie¯y, 25 Â 10 cm culture plates of subcon¯uent HeLa cells were cultured in methionine-free MEM with Trans 35 S-label overnight (0.5 MBq/ml) (ICN Radiochemicals, Thame). The cells were harvested by scraping and washed in ice-cold PBS. Following resuspension in 5 ml of immunoprecipitation buer (IPP buer) [500 mM NaCl, 10 mM Tris (pH 8.0), 0.1% Nonidet P40], cells were sonicated on ice (3 Â 30 s), centrifuged at 14 000 g for 15 min and the supernatant used as antigen.
For immunoprecipitation, 20 ml of patient serum were incubated with 0.5 ml of 4 mg/ml protein A±Sepharose CL4B (Sigma Chemicals, Poole, Dorset) in IPP buer overnight at 48C. Antibodybound Sepharose was washed three times with IPP buer and resuspended in 200 ml of IPP buer, combined with 50 ml of 35 S-labelled HeLa extract for 2 h with occasional mixing. After four washes with IPP buer, the immunoprecipitated proteins were denatured by boiling for 2 min in 40 ml sample buer, fractionated on 8% polyacrylamide gels [22] . Gels were then ®xed, enhanced by soaking for 1 h in Amplify (Amersham International plc, Little Chalfont, Bucks.) and precipitates visualized by autoradiography.
RESULTS
ANA patterns in SSc
Seven hundred and thirty-®ve patients with SSc were classed according to their ANA pattern on HEp-2 cells. Cytoplasmic or nuclear staining was observed with all sera, and ANA were present in 97%. ACA was identi®ed from the ANA pattern in 25% of sera. Of the remainder, 26.5% gave a homogeneous pattern, 21% a ®ne speckled pattern, and 14% a ®ne speckled and nucleolar pattern. Less frequently observed were a coarse speckled pattern in 7.3%, nucleolar only in 3.3% and cytoplasmic only in 2.9% of sera (Fig. 1) .
Anti-ENA in SSc
Anti-ENA were investigated by CIE on sera from all patients. ATA were detected in 157 (21%), antinRNP in 48 (6.4%) and anti-PM-Scl in 40 (5.3%), each being associated with homogeneous, coarse speckled and ®ne speckled ANA, respectively. AntiRo were detected in 36 patients and in six of these anti-La were also detected. Anti-Jo-1, anti-PL-7 or anti-Ku were present in serum from nine patients, and anti-U3 RNP were detected in serum from eight patients. Sera from patients with ACA were generally negative for anti-ENA with only three patients having anti-Ro (Table I) .
Immunoprecipitation results
Sera from 374 SSc patients (51%) were immunoprecipitated and while varying proportions of the ANA/anti-ENA categories listed in Table I were tested (ACA 17%, ATA 59%), the concentration of all 86 positives in the sera giving ®ne speckled or ®ne speckled with nucleolar staining patterns led to a greater proportion of these sera (74±75%) being tested. Banding patterns characteristic of the precipitation of RNAP III, RNAP I and III or RNAP I and III together with the non-phosphorylated form of RNAP II were detected (Fig. 2) in 3/86, 50/86 and 33/86 sera, respectively. We estimate that the overall frequency of these antibodies in SSc is not less than 86/735 (11.7%). None of the 86 sera had detectable ACA, ATA, anti-nRNP, anti-Ro, anti-La or anti-PM-Scl.
Other autoimmune diseases
Sera from 93 patients with ANA-positive autoimmune diseases other than SSc were also immunoprecipitated. Half of the 93 sera (46/93) contained antibodies producing ®ne speckled or ®ne speckled and nucleolar ANA. Eighteen of these contained antibodies to Ro or Ro and La that gave a nucleoplasmic stain virtually indistinguishable from that produced by the ARA present in the SSc sera. However, none of the 93 sera produced the characteristic banding patterns of ARA seen in the SSc sera. 
Clinical features of patients with ARA
Clinical details were available on 81/86 patients with ARA. The group was predominantly female (84%), aged between 20 and 71 yr at onset with a mean of 48 yr. Sixty-two patients were classi®ed as dcSSc and 19 as lcSSc with an overall mean skin score of 31. Internal organ involvement was noted in 53 patients, 35 had pulmonary ®brosis and 27 renal disease (17 in the absence of lung ®brosis). Myositis or cardiac involvement was present in 15 of the patients with lung or renal disease. The duration of disease ranged from 1 to 19 yr with a mean of 5.8 yr. Renal disease and pulmonary ®brosis were equally prevalent throughout the range, although organ involvement in general was more common in the 25 patients 4±6 yr from onset compared with those with the disease for <3 yr or >6 yr; the mean skin score was also higher in this group, but not statistically signi®cant (data not shown). One-third of patients had renal disease and this was of similar frequency in both patients with lcSSc (7/19) and dcSSc (20/62).
A comparison group of patients positive for ATA by CIE was selected from the 88 patients on whom immunoprecipitations had been carried out. Fortyone were classi®ed as dcSSc and 40 as lcSSc; consequently, they had a signi®cantly lower mean maximum skin score (18.6) and only 3/81 had renal disease. However, signi®cantly more patients had pulmonary ®brosis, but there was little dierence in the incidence of in¯ammatory muscle disease or cardiac involvement, and isolated pulmonary hypertension was not a feature of either group (Table II) .
DISCUSSION
From a relatively simple breakdown of ANA patterns, we have been able to segregate the major autoantibodies occurring in SSc. In common with most recent studies, positive ANAs were recorded in >95% of patients. The three most common SScspeci®c antibodies to ACA, ATA and ARA were present in almost 60% with the additional characterized autoantibodies to PM-Scl, Ro, La, nRNP and U3-RNP detected in a further 15%. Detection of one SSc-speci®c antibody, anti-Th-RNP, was not reliable and no results were recorded in this study. The percentage of characterized autoantibodies identi®ed was H8% lower than in those recorded by Okano et al. [8] . They detected anti-Th-RNP in 4% of patients and higher frequencies of ARA and U3-RNP, but virtually no anti-PM-Scl. Frequencies of anti-nRNP, anti-La, ACA and ATA were similar. Serum from 86 patients precipitated proteins characteristic of RNAP III with 83 also precipitating RNAP I. These antibodies are regarded as SSc speci®c and all these sera gave a ®ne speckled nucleoplasmic stain on HEp-2 cell substrate as previously observed [8] . This pattern was indistinguishable from that produced by anti-La, and since this antigen is known to associate with RNAP III transcripts [23] , it is possible that the same particles are being visualized by indirect immuno¯uorescence. The speckled nucleolar pattern originally described by Reimer et al. [5] as characteristic of RNAP I antibodies was not seen and only 13 patients gave additional nucleolar staining that was homogeneous in appearance.
Seventy-®ve per cent of SSc patients giving ®ne speckled ANA were analysed, providing an ARA frequency of 11.7%. This is higher than the 1±5% noted in studies on antibodies to RNAP I [5, 7] . A similar frequency of positives was observed by Kipnis et al. [4] , but a higher frequency (22%) was recorded by Okano et al. [8] . In the only other UK study identifying ARA, Harvey et al. [24] observed that 10% of their sera precipitated RNAP I and III; an additional 7.2% precipitated RNAP II in conjunction with ATA, but in the absence of the other polymerases. This association had previously been noted by Satoh et al. [12] and both studies showed that the dominant antigen was the phosphorylated form of the large subunit of RNAP II (RNAP IIO), but observed that the unphosporylated form (RNAP IIA) could also be precipitated. Unlike the SSc-speci®c association of RNAP I/III antibodies, RNAP II antibodies have also been detected in other connective tissue diseases [11] . Although RNAP IIA antibodies were found in association with other ARA, the broader range of RNAP II antibodies suggests that they should be considered separately from those speci®c to SSc and that epitope mapping will provide a clearer picture with regard to the ®ne speci®city of these antibodies. Also, the precipitation of RNAP IIO antibodies may be part of a more general phenomenon whereby autoantigens become more reactive with autoantibodies when phosphorylated [25] .
In earlier studies, the mutually exclusive nature of ACA and ATA has been documented [3] . It now appears that ARA form a third distinct subpopulation [8] with only a single example of coexistence between ARA and ATA reported to date [24] . The subgroup associated with ACA is almost entirely con®ned to those patients with limited skin thickening and little internal organ involvement, but in whom isolated pulmonary hypertension may be an important feature [3, 26] . We chose to compare the clinical features of the ARA-positive group, previously associated with diuse disease, with a similar number of ATA-positive patients. ATA is also predominantly associated with diuse disease or with a form of lcSSc with severe distal skin involvement and an increased incidence of pulmonary ®brosis [3] . The results con®rmed previous observations by Okano et al. [8] that the maximum mean skin score and the incidence of renal disease were signi®cantly higher in ARA patients. Conversely, the ATA patients had a signi®cantly higher incidence of pulmonary ®brosis, whereas the frequency of in¯ammatory muscle disease and cardiac involvement was similar in both groups.
While skin scores provide an indication of disease severity, both ARA-and ATA-positive patients were divided between the classi®cations of lcSSc and dcSSc. Within the ARA patient group, both classi®cations carried the same risk of renal disease and similarly in the ATA-positive patients the incidence of pulmonary ®brosis was not signi®cantly dierent whether patients were classi®ed as lcSSc or dcSSc. Thus, ARA and ATA are markers of particular clinical signi®cance in the lcSSc subset. Although skin scoring remains a useful measurement, particularly in patients without a de®ned autoantibody pro®le, the existence of mutually exclusive antibodies with well-de®ned and distinct patterns of organ involvement provides a more informative prognostic indicator.
In summary, ARA were identi®ed in sera from scleroderma patients. These sera all produced a ®ne speckled ANA and contained no other characterized autoantibodies. RNAP IIA antibodies were present as a subpopulation within the sera positive for antibodies to RNAP I and III. The presence of ARA identi®ed a clinical picture featuring extensive skin and renal involvement.
